When is tofacitinib indicated in the treatment of rheumatoid arthritis (RA)?

Updated: Feb 07, 2020
  • Author: Howard R Smith, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Tofacitinib is an oral JAK inhibitor [105] that was approved by the FDA in November 2012 as second-line treatment for moderate to severe active RA. [106] The indication is specific for patients who have had an inadequate response to or are intolerant of MTX. Tofacitinib may be given as monotherapy or in combination with MTX or other nonbiologic DMARDs. It should not be used in combination with biologic DMARDs or potent immunosuppressive agents (eg, azathioprine or cyclosporine).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!